[1] RAJKUMAR S V, DIMOPOULOS M A, PALUMBO A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15(12):e538-e548.
[2] 禹文君, 陈春苗, 欧阳晓俊, 等. 以老年消瘦、贫血、骨破坏为表现的轻链型多发性骨髓瘤1例[J]. 实用老年医学, 2020, 34(2):205-206.
[3] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订)[J]. 中华内科杂志, 2020, 59(5):341-346.
[4] VARETTONI M, CORSO A, PICA G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients[J]. Ann Oncol, 2010, 21(2):325-330.
[5] THOMAS F B, CLAUSEN K P, GREENBERGER N J. Liver disease in multiple myeloma[J]. Arch Intern Med, 1973, 132(2):195-202.
[6] TALERMAN A. Clinico-pathological study of multiple myeloma in Jamaica[J]. Br J Cancer, 1969, 23(2):285-293.
[7] ALEGRE A, MARTINEZ-CHAMORRO C, FERNANDEZ-RANADA J M. Massive myelomatous ascites responsive to VAD chemotherapy and autologous stem cell transplantation[J]. Bone Marrow Transplant, 1999, 24(3):343-344. |
